



INSTRUCTIONS FOR SCHOOL NURSE

Student name: _____

Physician name: _____

Physician signature: _____

Date: _____

Physician phone number: _____

Administer AFREZZA® at the beginning of each meal.^{1,2} If unable to do so, AFREZZA can be taken within 20 minutes following the first bite of food.³

Date	Breakfast dose	Lunch dose	Dinner dose	Correction or snack dose
	_____ units	_____ units	_____ units	_____ units

Postmeal correction threshold

☐ 160 mg/dL

☐ Other: _____

If needed, the AFREZZA dose may be adjusted as follows:

- 1. Premeal glucose:** +4 units to mealtime dose if premeal glucose is above _____ mg/dL.^{1,3}
- 2. Meal type:** +4 units to mealtime dose for an extra large carbohydrate meal or -4 units for an extra small carbohydrate meal.^{1,3}
- 3.** Changes cannot exceed ± 4 units from doses without physician approval.^{3,4}
- 4.** If a correction or snack dose is needed, be sure to wait 60 to 90 minutes after the last dose of AFREZZA to take another dose.³

Scan the QR code to view
an instructional video on
how to inhale AFREZZA.



Indications and Usage:

Afrezza® (insulin human) Inhalation Powder is a rapid-acting inhaled human insulin indicated to improve glycemic control in adult and pediatric patients 6 years of age and older with diabetes mellitus.

Limitations of Use: Not recommended for the treatment of diabetic ketoacidosis, not recommended in patients who smoke, or have recently stopped smoking.

Important Safety Information

WARNING: RISK OF ACUTE BRONCHOSPASM IN PATIENTS WITH CHRONIC LUNG DISEASE

- Acute bronchospasm has been observed in AFREZZA-treated patients with asthma and Chronic Obstructive Pulmonary Disease (COPD).
- AFREZZA is contraindicated in patients with chronic lung disease such as asthma or COPD.
- Before initiating AFREZZA, perform a detailed medical history, physical examination, and spirometry (FEV₁) to identify potential lung disease in all patients.

Please see additional Important Safety Information on the reverse side and scan the QR code on the back to access the full Prescribing Information, including **BOXED WARNING**, for AFREZZA.

Important Safety Information (continued)

Contraindications

AFREZZA is contraindicated: during episodes of hypoglycemia, in patients with chronic lung disease (such as asthma or COPD) because of the risk of acute bronchospasm, and in patients with previous severe hypersensitivity reaction to any regular human insulin product or any of the active ingredients in AFREZZA. Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with AFREZZA.

Warnings and Precautions

Acute Bronchospasm in Patients with Chronic Lung Disease: Serious risk of acute bronchospasm in patients with asthma and COPD. Prior to initiating therapy, evaluate patients with a medical history, physical examination, and spirometry (FEV₁) to identify potential underlying lung disease.

Hypoglycemia or Hyperglycemia with Changes in Insulin Regimen: Changes in an insulin regimen (e.g., insulin strength, manufacturer, injection site or type, or method of administration) may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Changes should occur under close medical supervision with increased frequency of blood glucose monitoring.

Hypoglycemia: Hypoglycemia is the most common adverse reaction of insulin therapy and may be serious and life-threatening. Advise patients to recognize and manage hypoglycemia and self-monitor glucose.

Decline in Pulmonary Function: AFREZZA has been shown to cause a decrease in lung function as measured by FEV₁. Assess pulmonary function with spirometry at baseline, after 6 months of therapy, and annually thereafter, even in the absence of pulmonary symptoms. In patients who have a decline of $\geq 20\%$ in FEV₁ from baseline, consider discontinuing AFREZZA. Consider more frequent lung function assessment in patients with pulmonary symptoms, e.g., wheezing, bronchospasm, breathing difficulties, or persistent or recurring cough. If symptoms persist, discontinue AFREZZA.

Lung Cancer: Available data are insufficient to determine whether AFREZZA has an effect on lung or respiratory tract tumors. In patients with active lung cancer, a prior history of lung cancer, or in patients at risk of lung cancer, consider whether the benefits of AFREZZA outweigh the risks.

Diabetic Ketoacidosis (DKA): In patients at risk for DKA, increase the frequency of glucose monitoring and consider discontinuing AFREZZA.

Hypersensitivity Reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, can occur. Discontinue AFREZZA, monitor, and treat if indicated.

Hypokalemia: Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk of hypokalemia.

Fluid Retention and Heart Failure with Concomitant Use of PPAR-gamma Agonists: Fluid retention, which may lead to or exacerbate heart failure, can occur with concomitant use of proliferator-activated receptor (PPAR)-gamma agonists (thiazolidinediones) and insulin. Observe these patients for signs and symptoms of heart failure. If heart failure occurs, consider dose reduction or discontinuation of PPAR-gamma agonists.

Adverse Reactions

The most common adverse reactions associated with AFREZZA include hypoglycemia, cough, and throat pain or irritation.

Drug Interactions

Certain drugs may affect glucose metabolism, dosage modification and increased frequency of blood glucose monitoring may be required. Co-administration of beta-blockers, clonidine, guanethidine, and reserpine with AFREZZA may reduce the signs and symptoms of hypoglycemia. For complete list, see full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact MannKind Corporation at 1-877-323-8505 or FDA at www.fda.gov/medwatch or call 1-800-FDA-1088 (1-800-332-1088).

References: 1. AFREZZA. Prescribing information. MannKind Corporation; 2026. 2. AFREZZA. Instructions for use. MannKind Corporation; 2026. 3. Haller MJ, Kanapka L, Monzavi R, et al; INHALE-1 Study Group. INHALE-1: a multicenter randomized trial of inhaled Technosphere insulin in children with type 1 diabetes. *Diabetes Care*. 2026;49(1):179-187. 4. AFREZZA. Medication guide. MannKind Corporation; 2026.

Please see additional Important Safety Information on the reverse side and scan the QR code on the right to access the full Prescribing Information, including **BOXED WARNING**, for AFREZZA.

Scan for full
Prescribing Information
for AFREZZA.



mannkind

AFREZZA, the AFREZZA logo, MannKind, and the MannKind logo are registered trademarks of MannKind Corporation.
© MannKind Corporation May 2026. US-AFR-3047

 **afrezza**
(insulin human) Inhalation Powder